Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Status Recruiting

Clinical Trial Summary

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05581550
Study type	Interventional
Source	National Cancer Centre, Singapore
Contact	Wen Long Nei, MD
Phone	+65 6436 8000
Email	nei.wen.long@singhealth.com.sg
Status	Recruiting
Phase	N/A
Start date	June 29, 2020
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00370890` - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy	Phase 3
Recruiting	`NCT04340024` - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Completed	`NCT00697619` - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer	Phase 2
Completed	`NCT00078546` - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)	Phase 1
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Active, not recruiting	`NCT01074021` - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer	Phase 3
Active, not recruiting	`NCT03890185` - Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC	Phase 2
Not yet recruiting	`NCT04158414` - Applying PET/MR in Oncology - a Prospective Project	N/A
Completed	`NCT02608073` - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer	Phase 2
Completed	`NCT03656250` - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT04476641` - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors	Phase 2
Terminated	`NCT03144661` - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies	Phase 1
Not yet recruiting	`NCT06414577` - Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy	Phase 2
Recruiting	`NCT03003182` - A Study of Nasopharyngeal Carcinoma From Guangdong	N/A
Not yet recruiting	`NCT06349889` - Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma	Phase 2
Completed	`NCT01094405` - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy	Phase 2
Not yet recruiting	`NCT05305131` - Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer	Phase 2
Completed	`NCT01800071` - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma	Phase 1
Recruiting	`NCT00304694` - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients	N/A